I am confident that Gottlieb, who always was a proponent of on-time evaluations and fast-tracks, where warranted, is familiar with AUPH and its test results.
It would be very surprising if he's not. He's part of the team at NEA Managment, which includes AUPH among it's 54 largest positions with over 5M shares.
He also worked for GSK at one time so he's probably more than familiar with LN.
Today’s conference will bring a lot of market exposure for AUPH, I believe we”ll hear an endorsement by Gottlieb referring to FDA approval. Nothing but up from here